ADMA Biologics Inc (NASDAQ:ADMA) Receives Average Rating of “Hold” from Analysts

ADMA Biologics Inc (NASDAQ:ADMA) has been given a consensus recommendation of “Hold” by the six brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $19.6667.

ADMA has been the topic of several analyst reports. Cantor Fitzgerald reissued a “neutral” rating on shares of ADMA Biologics in a report on Thursday, March 26th. Raymond James Financial began coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 price objective for the company. Wall Street Zen lowered shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Mizuho dropped their price objective on ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Finally, Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 26th.

ADMA Biologics Price Performance

ADMA Biologics stock opened at $8.61 on Friday. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of 12.66 and a beta of 0.73. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. ADMA Biologics has a 12 month low of $7.21 and a 12 month high of $20.46. The stock’s 50 day moving average is $8.78 and its 200-day moving average is $13.11.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.19. The company had revenue of $114.49 million during the quarter, compared to the consensus estimate of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company’s revenue was down .3% on a year-over-year basis. During the same quarter last year, the firm earned $0.11 earnings per share. Equities research analysts expect that ADMA Biologics will post 0.82 EPS for the current year.

Insiders Place Their Bets

In other news, Director Jerrold B. Grossman bought 12,500 shares of the stock in a transaction on Monday, May 11th. The stock was acquired at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director directly owned 513,884 shares in the company, valued at approximately $4,116,210.84. This trade represents a 2.49% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.90% of the stock is owned by corporate insiders.

Institutional Trading of ADMA Biologics

Several institutional investors have recently modified their holdings of the business. Boothbay Fund Management LLC bought a new position in shares of ADMA Biologics during the 3rd quarter valued at about $11,334,000. Tealwood Asset Management Inc. bought a new stake in ADMA Biologics in the 4th quarter worth approximately $1,315,000. American Century Companies Inc. lifted its position in ADMA Biologics by 1.8% in the 3rd quarter. American Century Companies Inc. now owns 4,695,923 shares of the biotechnology company’s stock worth $68,842,000 after buying an additional 84,934 shares during the last quarter. First Light Asset Management LLC boosted its stake in ADMA Biologics by 12.3% in the third quarter. First Light Asset Management LLC now owns 1,069,233 shares of the biotechnology company’s stock worth $15,675,000 after buying an additional 117,137 shares in the last quarter. Finally, B Group Inc. boosted its stake in ADMA Biologics by 4.1% in the third quarter. B Group Inc. now owns 2,412,542 shares of the biotechnology company’s stock worth $35,368,000 after buying an additional 95,000 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics News Roundup

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: The company’s own financial backdrop is not weak: ADMA previously reported EPS in line with expectations and posted strong profitability metrics, which could help support investor confidence if legal issues are resolved.
• Neutral Sentiment: Multiple law firms announced August 10, 2026 lead-plaintiff deadlines and encouraged affected investors to join or lead the class action, keeping the lawsuit in the spotlight but adding no new business fundamentals. Article Title
• Neutral Sentiment: Lowey Dannenberg and other firms said they are investigating ADMA for possible federal securities law violations, extending the legal uncertainty around the stock. Article Title
• Negative Sentiment: A new securities-fraud class action alleges ADMA made misleading statements about revenues and internal controls during the August 2024 to March 2026 period, raising the risk of damages, legal costs, and further headline risk. Article Title
• Negative Sentiment: Earlier allegations that ADMA concealed channel stuffing and an undisclosed related-party distributor continue to drive the stock’s legal overhang and may keep shares volatile. Article Title

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.